Stem Cells

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

Retrieved on: 
星期三, 五月 8, 2024
Radiology, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hospitals, Genetics, Data Management, Stem Cells, Science, Practice Management, Technology, Clinical Trials, Medical Supplies, FDA, Biotechnology, Surgery, Health, CO, Cancer, Depreciation, Webcast, DdPCR, Forecasting, Growth, MSKCC, Net operating loss, Patient, COVID-19, Acquisition, Adjustment, AACR, Bank statement, EGFR, GAAP, AstraZeneca

In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.

Key Points: 
  • In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
  • Our team is off to a strong start, helping to impact more patients every quarter in the large and underserved lung nodule diagnostic testing market.
  • Record quarterly gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023.
  • The Company reaffirms its 2024 financial outlook and expects to generate between $65 million and $68 million in total revenue in 2024.

Precision BioSciences to Report First Quarter Results on May 13, 2024

Retrieved on: 
星期二, 五月 7, 2024
FDA, Other Health, Technology, Nanotechnology, Stem Cells, Pharmaceutical, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Gene editing, Precision BioSciences

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Induced Pluripotent Stem Cell (iPSC) Industry Market Size, Trends, and Forecast Report - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 7, 2024
Health, Stem Cells, OA, Cellular Dynamics International, University, Microsoft Exchange Server, Cell, CRISPR, Safety, Drug development, Osteoarthritis, World Games, MSC, Partnership, Research, CLI, B cell, Application, Disease, Human, Therapy, Patient, COVID-19, Tissue engineering, Graft-versus-host disease, IPSC, Medicine, Kyoto University, 3D bioprinting, Macular degeneration, Regenerative medicine, CDI, Clinical trial, Toxicology, Drug discovery, Personalized medicine, Merck, Thermo Fisher Scientific, Pharmaceutical industry

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
    Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development.

NIH Awards Hesperos Research Grant to Develop Animal-Free Botox Testing Platform

Retrieved on: 
星期二, 五月 7, 2024
Health, FDA, Stem Cells, Research, Science, Pharmaceutical, Biotechnology, NMJ, NIH, Safety, Food, Cell, Animal, Acetylcholine, Spasticity, Botulinum toxin, MLB, Santhanam, Neurotoxin, Brain cell, Strabismus, Biology, Paralysis, Drug development, NCATS, Migraine, Drug discovery, Neuromuscular junction, Pharmaceutical industry

The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.

Key Points: 
  • The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.
  • Despite its therapeutic benefits, BoT is one of the most potent neurotoxins known to man, necessitating stringent batch testing to ensure consistent potency.
  • By successfully developing a high-throughput, human-based platform, Hesperos endeavors to obviate the need for animal testing in this process while simultaneously enhancing the safety profile of BoT.
  • https://fda.gov
    The mission of National Center for Advancing Translational Sciences (NCATS) at NIH is to turn research observations into health solutions through translational science.

Colossal Biosciences’ Thylacine Gene-Editing Technologies Provide Hope for Australia’s Endangered Northern Quoll

Retrieved on: 
星期三, 五月 8, 2024
Research, Environmental Issues, Environmental Health, Environment, University, Genetics, Education, Science, Biotechnology, Stem Cells, Other Science, Health, Leg, School, Organization, Deakin University, Curtin University, Ecosystem, Cell, CRISPR, Fibroblast, Colossal Biosciences, Convulsion, Risk, Genetic engineering, De-extinction, Saliva, Animal, Survival, Death, University of Melbourne, Gene editing, Doctor of Philosophy, Rhinella, Ecology, Life, Vertebrate, Food, Invertebrate, IPSC, Neurotoxin, Multimedia, Paralysis, Snake, Quoll, Reptile, Hunting

Since the introduction of invasive cane toads (Rhinella marina) in Queensland in the 1930s, the northern quolls have seen their populations plummet by 75% .

Key Points: 
  • Since the introduction of invasive cane toads (Rhinella marina) in Queensland in the 1930s, the northern quolls have seen their populations plummet by 75% .
  • Cane toads have now become an attractive food source for the northern quoll, which is especially vulnerable to the toad’s neurotoxins.
  • “It’s thrilling to see our de-extinction work for the Thylacine providing technology solutions for living endangered marsupials,” said Sara Ord, Director of Species Restoration at Colossal.
  • Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth.

Bio-Rad Reports First-Quarter 2024 Financial Results

Retrieved on: 
星期二, 五月 7, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Acquisition, Table, Webcast, Bank statement, Forecasting, Nature, GAAP, Growth, EPS, Bio-Rad Laboratories, Bank

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • Management will discuss the company’s first quarter 2024 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on May 7, 2024.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.

bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy

Retrieved on: 
星期一, 五月 6, 2024
Research, Genetics, Clinical Trials, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Sickle cell disease, FDA, Bluebird, Silver, Cell, Hope, Anti-transglutaminase antibodies, MD, Partnership, History, Patient, Caregiver, MBA, Genetic disorder, Bluebird bio

bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events.

Key Points: 
  • bluebird bio, Inc. (Nasdaq: BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events.
  • LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy for sickle cell disease, with the longest follow-up in the field.
  • “Seeing people living with sickle cell disease receive gene therapy in the real world is a vision that has fueled bluebird for more than 10 years,” said Andrew Obenshain, president and CEO, bluebird bio.
  • QTCs are selected based on leading expertise in transplant, cell and gene therapy, and sickle cell disease and receive specialized training to administer LYFGENIA.

Vizgen Announces Significant Win in Ongoing Patent Litigation Against 10x Genomics and Harvard University

Retrieved on: 
星期二, 五月 7, 2024
Stem Cells, Biotechnology, Professional Services, Health, General Health, Patent Law, Health Technology, Research, Genetics, Legal, Science, Harvard University, Chromium, Harvard College, District court, Court, Defendant, Genomics, Ridesharing

Vizgen, Inc. , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University.

Key Points: 
  • Vizgen, Inc. , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University.
  • The U.S. District Court recently ruled in Vizgen’s favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation.
  • The Court’s ruling substantially strengthens Vizgen’s position against 10x Genomics and Harvard, who must now defend against additional allegations of antitrust violations.
  • 10x Genomics, Inc. and President and Fellows of Harvard College, Plaintiffs, v. Vizgen, Inc., Defendant.

Arcellx to Participate in Two Upcoming Investor Conferences

Retrieved on: 
星期二, 五月 7, 2024
Research, Clinical Trials, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer, Patient, Fireside chats, Communications satellite

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences:

Key Points: 
  • Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences:
    Presentation: Tuesday, May 14 at 3:40 p.m. PT
    Fireside Chat: Tuesday, May 28 at 1:00 p.m. PT
    A live webcast of these discussions will be accessible from Arcellx’s website at www.arcellx.com in the Investors section.
  • A replay of the webcasts will be archived and available for 30 days following the event.

KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance

Retrieved on: 
星期五, 五月 3, 2024
Research, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Contract research organization, Vitruvian Partners, Partnership, Investment, Partner, Flow cytometry

KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia.

Key Points: 
  • KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia.
  • John Bucksath, CEO of KCAS Bio, commented, “We are delighted to partner with the Crux Biolabs team, working to accelerate our combined offering of global development support to the industries and customers we serve.
  • KCAS Bio has embarked on significant investments in spectral flow cytometry, including the placement of harmonized Cytek Aurora cytometers at Crux Biolabs.
  • Establishing common practices and using a harmonized Cytek Aurora platform for spectral flow cytometry with KCAS Bio will bring a unique and industry-leading offering to our current and emerging clients.”